

Index

A

- Acetaminophen, 17
- Activities of daily living (ADL), 186–187, 229
- Acute intracerebral hemorrhage, 202–203
- Acute Stroke Ischemic NXY-059 Treatment (SAINT), 304
- Agnosia, 322, 332
- Alzheimer’s disease (AD), 169, 170
- American Heart Association (AHA) guidelines, 16, 17
- American Heart Association Stroke Outcome Classification (AHA.SOC), 290
- Aneurysmal subarachnoid hemorrhage (aSAH)
 - clipping vs. coiling, 188
 - encephalomalacia, 189
 - pSAH survivors, 190
 - ruptured aneurysms, 189
 - cognitive outcome
 - attention, 179–180
 - executive function, 182–185
 - language, 185
 - memory, 181–182
 - visuospatial function, 185–186
 - CT angiography, 178
 - functional outcome
 - daily living activities, 186–187
 - instrumental activities of daily living, 187
 - return to work, 187–188
 - incidence, 178
 - neuroimaging, 190–191
 - prognostic factors, 284
 - risk factors, 177
 - thirty-day case fatality rate, 178, 179
- Anomic aphasia, 101
- Anterior cerebral artery infarcts, 141
- Anterior communicating artery (ACoA), 182, 183
- Aphasia, 122, 123, 327–330. *See also* Post-stroke aphasia (PSA)
- Apoplexy, 1
- Apraxia
 - classification
 - errors in performance, 54
 - representational/nonrepresentational gesture, 53–54
 - single-gesture performance, 52
 - task and input modality, 52
 - tool/object use, 52
 - clinical assessment implications, 61–62
 - cognitive rehabilitation and recovery, 322, 331
 - functional performance
 - after intervention, 64
 - conceptual system, 64
 - functional dependency, 62–63
 - gesture production, 65
 - observational perspective, 62
 - severity, 63
 - models
 - conceptual, 60
 - production systems, 60–61
 - routes to action, 61
 - sensory-perceptual, 60
 - neural correlation
 - callosal lesions, 57
 - hand gestures, 59
 - hemispheric asymmetries, 55–56
 - left hemisphere, 57–59
 - neuroimaging, 58, 59
 - stroke, 57
 - voxel-based lesion, 56

- Arcuate fasciculus, 98, 100, 101, 104, 106
- Arterial spin labeling (ASL)
 Alzheimer disease, 274
 arterial transit time, 274
 BOLD signal, 273
 CBF-weighted, 272, 273
 RF pulses, 272
- B**
- Behavioral disorder. *See* Dysexecutive syndrome
- Beta-amyloid, 209, 210
- Bloodletting, 2
- Blood oxygenation level-dependent fMRI
 phases, 267
 resting-state, 271–272
 task-based, 269–271
- Boston naming test (BNT), 154, 156
- Brain microbleeds
 CAA, 208
 hemosiderin, 207
 magnetic resonance imaging, 264
 MRI T2*-weighted gradient-recalled echo, 207
- British Aneurysm Nimodipine Trial, 302
- Broca's aphasia, 99–100, 124
- C**
- CAA. *See* Cerebral amyloid angiopathy (CAA)
- CADASIL. *See* Cerebral autosomal dominant arteriopathy with subcortical ischemic leukoencephalopathy (CADASIL)
- Callosal apraxia, 53
- Cardio-embolic stroke, diagnosis, 6–7
- Cardiogenic brain embolism, sources of, 9
- Carotid endarterectomy, 10
- Cerebellar stroke, 26
- Cerebral amyloid angiopathy (CAA)
 abeta, 209
 Alzheimer's disease, 209
 amyloid, 208
 Boston criteria, 210
 brain autopsy, 211
 factors, 212
 lobar microbleeds, 210
- Cerebral autosomal dominant arteriopathy with subcortical ischemic leukoencephalopathy (CADASIL), 212–213
- Cerebral small vessel disease, 7
- Cerebral venous thrombosis, 218
- Chedoke-McMaster stroke assessment scale, 290
- CNS vasculitis, 213–214
- Cognitive disorder. *See* Dysexecutive syndrome
- Cognitive rehabilitation and recovery
 aims, 317–318
 Cochrane reviews, 317, 325, 327, 331, 335
 comprehensive neuropsychological rehabilitation models
 evidence base, 333
 inclusions, 332
 multidisciplinary team services, 333
 stepped care model, 333, 334
 UK guideline, 332, 333
 definition of, 318
 domain-specific recommendations
 agnosia, 322, 332
 aphasia, 327–330
 apraxia, 322, 331
 attention, 323–325
 Canadian recommendations, 323
 concentration, 323–325
 executive functions, 322, 331
 memory impairments, 324–327
 neglect, 327, 328
 perception, 332
 impacts, 315
 psychological problems, 316
 quality of, 316–317
 randomized controlled trials, 316, 324, 327, 333
 screening and assessment
 general, 322
 national clinical stroke guidelines, 317–320
 Scottish guidelines, 318
 timing and workforce mobilization, 320–322
- Conduction aphasia, 100
- Constraint induced movement therapy, 37
- Contrast-enhanced magnetic resonance angiography (CE-MRA), 263
- Covert brain infarcts, 6
- D**
- Decompressive craniectomy, 24–26, 304–305
- Desmoteplase, 19
- Diffusion tensor imaging (DTI)
 EPI techniques, 266
 FA value, 266
 tractography, 267, 268

- Diffusion-weighted imaging (DWI), 261
 Disconnection syndrome, 84–85
 Double-step saccade task, 80
 Drug therapy, PSA, 110–112
 DTI. *See* Diffusion tensor imaging (DTI)
 Dural arteriovenous fistula, 219
 Dysexecutive syndrome
 clinical implications
 attention, 144
 cognitive assessment, 144, 145
 gaze abnormalities, 144
 monitoring and regulation, 145
 motor sequence, 144
 neuropsychological examination, 144
 NIH scale score, 143
 functions and disorders
 abulia-apathy, 141, 142
 action speed and slowing, 137, 138
 akinetetic mutism, 141, 143
 anterior cerebral artery infarcts, 141
 apathy, 138
 aspects of, 135, 136
 behavioral and cognitive disorders, 136, 137
 cerebral infarction, 140, 141
 cerebral venous thrombosis, 138, 143
 confusional states, 141
 deficit profile, 138
 definition, 135
 determinants of, 140
 facilitatory paratonia, 144
 frontal lobe damage, 136, 137
 GREFEX study, 136, 137
 heteroactivation, 141
 hypoactivity, 138, 141–143
 impairment, 139
 infarcts, 140, 141
 intracerebral hemorrhage, 143
 lacunar infarcts, 142
 oppositional paratonia, 144
 psychomotor speed, 143
 reaction time test, 137
 subarachnoid hemorrhage, 142–143
 thalamic dementia, 142
 thalamic infarcts, 141–142
 verbal fluency test, 138
- E**
 Echo planar imaging (EPI), 260
 Electroconvulsive therapy (ECT), 234–235
 Electrodermal activity (EDA), 270, 271
 Elevator counting task, 76
 Embolic stroke, mechanisms of, 8
- Emotional communication disorders
 classification and domains, 119
 facial emotion
 anterior *vs.* posterior lesions, 128
 expressions, 128–129
 hemispheric strokes, 125–127
 iconic hypothesis, 127
 LHD patients, 127, 128
 mirror-somatosensory hypothesis, 128
 neutral facial discrimination, 126
 nonverbal emotions, 127
 RHD patients, 126–128
 ventral temporal-occipital lesion, 128
 visuospatial facial perceptual disorder, 126, 127
 speech (*see also* Speech emotion disorders)
 expression, 123–125
 prosody, 120–122
 verbal stimuli, 122–123
- Episodic memory
 familiarity, 152
 hippocampus
 anterograde and retrograde amnesia, 160, 161
 familiarity-based memory, 158
 hypoxic ischemic encephalopathy, 159
 left *vs.* right, 160
 medial temporal lobe, 160
 multiple trace theory, 158
 recollection, 158, 159
 and posterior association areas, 167–169
 prefrontal cortex
 aneurysm ruptures, 166
 confabulation, 165
 impairment, 164
 left *vs.* right, 167
 top-down deficit, 165
 recollection, 152
 and thalamus (*see* Thalamus)
- EuroQol, 289, 303
 Explicit memory, 152
 EXPRESS study, 9
- F**
 Facial action scoring system (FACS), 128
 Facial emotion disorders. *See* Emotional communication disorders
 Fisher grade, 180
 Fluid-attenuated inversion recovery (FLAIR), 261
 Fluoxetine, 230
 Frenchay activities index, 290
 Frontal lobe, 182–184

G

- Gadolinium diethyl-triamine-penta-acetic acid (Gd-DTPA), 263
- Glasgow Outcome Scale (GOS), 184, 185
- Global aphasia, 100–101
- GREFEX study, dysexecutive syndrome, 136–138

H

- Health-related quality of life (HRQoL)
 - primary caregivers, 248–250
 - SIP and NHP, 245
 - standard-gamble method, 243
 - time-tradeoff method, 243
 - utility index, 244
- Hematoma, 29, 30
- Hemispheric strokes, 123, 125–127
- Hemorrhagic stroke
 - acute medical management, 28
 - core area, 15
 - ICH, 24, 26, 27
 - IVH, 28
 - SAH, 24, 27
 - surgical treatment, 29–30
- Hippocampus
 - anterograde and retrograde amnesia, 160, 161
 - familiarity-based memory, 158
 - hypoxic ischemic encephalopathy, 159
 - left vs. right, 160
 - medial temporal lobe, 160
 - multiple trace theory, 158
 - recollection, 158, 159
- HRQoL. *See* Health-related quality of life (HRQoL)
- Hunt and Hess grade, 180, 186
- Hyperglycemia, 17, 285
- Hypertension, 16, 17
- Hypoglycemia, 17
- Hypotension, 17
- Hypothermia, 17
- Hypoxic ischemic encephalopathy, 159

I

- ICH. *See* Intracerebral hemorrhage (ICH)
- Iconic hypothesis, 127
- Ideational apraxia, 52
- Ideomotor apraxia (IMA), 52
- Imitation, 52
- Implicit memory
 - basal ganglia and cerebellum, 156

- neuropsychological measures, 154
- priming, 152
- procedural, 152
- Infarcts, 140–143
- Instrumental activities of daily living (IADL), 187
- International Stroke Trial, 302
- International Subarachnoid Aneurysm Trial (ISAT), 303
- International Surgical Trial in Intracerebral Hemorrhage (STICH), 304
- Intracerebral hemorrhage (ICH).
 - See also* Hemorrhagic stroke
 - bleeding into parenchyma, 24–27
 - cerebral amyloid angiopathy
 - abeta, 209
 - Alzheimer's disease, 209
 - amyloid, 208
 - Boston criteria, 210
 - brain autopsy, 211
 - factors, 212
 - lobar microbleeds, 210
 - cognitive consequences
 - aphasia, 205
 - caudate nucleus and putamen, 205
 - cerebral amyloid angiopathy, 203
 - dementia, 203
 - leukoaraiosis, 203, 204
 - MoCA, 204
 - neuropsychological testing, 204
 - striatum, 205
 - WCST, 205
 - cognitive symptoms/signs
 - basal ganglia, 202
 - delirium, 203
 - thalamus, 202
 - diagnosis and medical management, 206–207
 - dysexecutive syndrome, 143
 - etiology and epidemiology, 26
 - cerebral amyloid angiopathy, 200, 201
 - incidence, 200
 - locations, 202
 - primary and secondary causes, 201
 - ischemic stroke
 - CADASIL, 212–213
 - cerebral venous thrombosis, 218
 - dural arteriovenous fistula, 219
 - hypercoagulability and hyperviscosity states, 218
 - intravascular large B cell lymphoma, 214
 - moyamoya syndrome, 215–217
 - sickle cell disease, 217–218

- systemic lupus erythematosus, 215
- vasculitis, 213–214
- microbleeds
 - CAA, 208
 - hemosiderin, 207
 - MRI T2*-weighted gradient-recalled echo, 207
 - surgical treatment, 29–30
- Intravascular large B cell lymphoma, 214
- Intraventricular hemorrhage (IVH).
 - See* Hemorrhagic stroke
- Ischemic stroke
 - acute medical management
 - AHA guidelines, 16, 17
 - fever, 17
 - hypoglycemia and hyperglycemia, 17
 - hypotension and hypertension, 16, 17
 - imaging techniques, 17
 - arterial occlusion, 16
 - causes, 15
 - complications, 11
 - core area, 15
 - decompressive craniectomy, 24–26
 - etiology, 5
 - interventions, 10
 - intra-arterial and mechanical
 - thrombolysis, 21
 - advantages, 20
 - basilar occlusion, 24
 - combination therapy, 22
 - embolectomy, 22, 23
 - IMS II trial, 22
 - MELT trial, 20
 - MERCI trial, 22
 - pro-urokinase and urokinase, 20
 - retrievable stent strategies, 22, 23
 - rtPA, 22
 - stent-assisted recanalization, 24
 - use of, 20
 - intracerebral hemorrhage
 - CADASIL, 212–213
 - cerebral venous thrombosis, 218
 - dural arteriovenous fistula, 219
 - hypercoagulability and hyperviscosity states, 218
 - intravascular large B cell lymphoma, 214
 - moyamoya syndrome, 215–217
 - sickle cell disease, 217–218
 - systemic lupus erythematosus, 215
 - vasculitis, 213–214
 - intravenous thrombolysis, 18–19
 - treatment, 15
- L**
- Lacunar infarcts, 142
- Large vessel disease, 5
- Left-hemisphere damage (LHD).
 - See* Emotional communication disorders
- Leukoaraiosis, 203, 204
- Limb apraxia. *See* Apraxia
- Limb-kinetic apraxia, 53
- M**
- Magnetic resonance imaging (MRI)
 - acute stroke
 - CE-MRA, 263
 - cerebrospinal fluid, 261
 - components, 261, 262
 - 3DTOF, 263
 - Gd-DTPA, 263
 - recombinant tissue plasminogen activator, 262
 - T2*-weighted images, 264
 - aneurysmal subarachnoid hemorrhage, 182, 183, 190
 - arterial spin labeling
 - Alzheimer disease, 274
 - arterial transit time, 274
 - BOLD signal, 273
 - CBF-weighted, 272, 273
 - RF pulses, 272
 - BOLD fMRI, 267, 269
 - development, 260
 - diffusion tensor imaging
 - EPI techniques, 266
 - FA value, 266
 - tractography, 267, 268
 - intervention and rehabilitation, 277
 - multi-parametric MRI protocols, 276
 - nuclear magnetic resonance
 - (*see* Nuclear magnetic resonance (NMR))
 - physical principles, 258–259
 - resting-state fMRI, 271–272
 - in stroke recovery, 264
 - stroke symptoms, 264–266
 - task-based fMRI, 269–271
- Malignant edema, 25

Memory loss

- Boston naming test, 156
- declarative memory, 153
- episodic (*see also* Episodic memory)
 - measurement, 153
 - neuronal damage, 157
- explicit memory, 152
- hippocampus (*see also* Hippocampus)
 - left vs. right, 160
 - multiple trace theory, 158
 - recollection vs. familiarity, 158–160
- implicit memory, 152
- long-term memory, 153
- neuropsychological measures, 154–155
- posterior association areas, 167–169
- post-stroke dementia
 - Alzheimer's disease, 170
 - large vessel, 169
 - mixed, 169
 - vascular, 169, 170
- prefrontal cortex
 - aneurysm ruptures, 166
 - confabulation, 165
 - impairment, 164
 - left vs. right, 167
 - top-down deficit, 165
- semantic memory, 153
- short-term memory, 152, 153
- thalamus
 - hippocampal damage, 163
 - left vs. right, 164
 - medial dorsal thalamic nuclei, 161
 - medial temporal lobe structures, 162
- Mini-Mental State Exam (MMSE), 230
- Mirror-somatosensory hypothesis, 128
- Modified Rankin Scale (mRS), 287
- Montreal Cognitive Assessment tool (MoCA), 204
- Moyamoya syndrome, 215–217
- MRI. *See* Magnetic resonance imaging (MRI)

N

- National clinical guidelines, 317–320
- National Institutes of Health Stroke Scale (NIHSS), 288, 289
- Neglect syndrome. *See also* Spatial neglect syndrome
 - cognitive rehabilitation and recovery, 327, 328
 - critical lesions, 81–84
 - disconnection syndrome, 84–85
 - spatial attention-based models, 74, 75

Neuropsychological rehabilitation.

See Cognitive rehabilitation and recovery

- North American Symptomatic Carotid Endarterectomy Trial (NASCET), 303
- Nottingham Health Profile (NHP), 245
- Nuclear magnetic resonance (NMR), 259

P

- Pantomime, 52
- Pathophysiology, 10–11
- Penumbra, 15
- Perimesencephalic subarachnoid hemorrhage (pSAH), 177, 190
- PFC. *See* Prefrontal cortex (PFC)
- Pharmacotherapy, PSA, 108–109
- Phonemes, 120
- Posterior fossa decompression, 26
- Post-stroke aphasia (PSA)
 - aphasia
 - acute, 96, 98
 - communication, 95
 - conceptualization of, 96
 - definition, 95
 - ischemic and subcortical infarctions, 96
 - National Aphasia Association reports, 96
 - quality of life, 96, 103
 - rehabilitation settings, 96
 - thalamic, 97
 - assessment of
 - aforementioned cognitive impairments, 103
 - cognitive neuropsychological approach, 102, 103
 - diagnosis, 102
 - language deficits evaluation, 102, 104
 - screening test, 102, 103
 - standardized aphasia test, 102, 103
 - classification of
 - algorithm of, 98, 99
 - anomic, 101
 - anterior perisylvian and extrasylvian, 97
 - Broca's aphasia, 97–100
 - clinical perspective, 98
 - conduction, 100
 - global, 100–101
 - impaired and preserved repetition, 98
 - lesion-symptom mapping, 98
 - transcortical, 98, 101
 - Wernicke's aphasia, 100
 - multidimensional approach, 102–104

- prognosis and recovery process
 - cerebral artery, 104, 105
 - diffusion tensor imaging, 106
 - environmental contingencies, 105
 - mechanisms, 104, 105
 - MRI, 106
 - patient's characteristics, 105
 - patterns of, 105
 - tractography, 107
 - treatment interventions
 - brain stimulation, 109
 - drug therapy, 110–112
 - epidural stimulation, 109
 - pharmacotherapy, 108–109
 - speech-language therapy, 107–108
 - Post-stroke dementia
 - Alzheimer's disease, 170
 - intracerebral hemorrhage, 203
 - large vessel, 169
 - mixed, 169
 - vascular, 169, 170
 - Post-stroke depression (PSD)
 - antidepressant medication, 230–232
 - cognitive consequences, 230
 - diagnosis
 - aphasia, 229
 - DSM-IV-TR, 228
 - rating scales, 228
 - mortality, 231
 - non-pharmacological treatments
 - behavioral interventions, 233–234
 - electroconvulsive therapy, 234–235
 - prevention, 235–236
 - psychotherapy, 234
 - repetitive transcranial magnetic stimulation, 234
 - pharmacological treatment, 232–233
 - physical and functional consequences, 229
 - psychostimulants, 233
 - social consequences, 231
 - Post-traumatic stress disorder (PTSD), 248, 250
 - Prefrontal cortex (PFC)
 - aneurysm ruptures, 166
 - confabulation, 165
 - impairment, 164
 - left vs. right, 167
 - sensorimotor control, 41–42
 - top-down deficit, 165
 - Prism adaptation process, 85–88
 - Prosody. *See* Speech emotion disorders
 - PSA. *See* Post-stroke aphasia (PSA)
 - PSD. *See* Post-stroke depression (PSD)
 - Psychostimulants, 233
- Q**
- Quality-adjusted life-year (QALY), 242, 243
 - Quality of Life (QoL)
 - burden of care, 250
 - caregivers, 248–250
 - coping strategies, 246
 - depression, 247
 - drug A and B, 243
 - HRQoL
 - SIP and NHP, 245
 - standard-gamble method, 243
 - time-tradeoff method, 243
 - utility index, 244
 - pain, 241
 - post-stroke depression, 246, 248
 - posttraumatic stress disorder, 248
 - QALY, 242, 243
 - sexual dysfunction, 246
 - subarachnoid hemorrhage, 247
- R**
- Recombinant tissue plasminogen activator (rtPA), 18–20, 22, 262
 - Repetitive transcranial magnetic stimulation (rTMS), 234
 - Resting-state fMRI (rs-fMRI), 271–272
 - Rey-Osterrieth Complex Figure-Recall subtest, 181, 186
 - Right-hemisphere damage (RHD). *See* Emotional communication disorders
- S**
- Saccadic remapping, 80, 81
 - Scottish guidelines, 318
 - Selective serotonin reuptake inhibitor (SSRI), 230
 - Sensorimotor control
 - constraint induced movement therapy, 37
 - fMRI scans, 40, 41
 - MRI scan, 39
 - N20-P27 amplitudes, 38, 39
 - perceptual thresholds, 38–40
 - PFC influences, 41–42
 - recovery process
 - aerobic training, 44
 - bimanual movement training, 43
 - brain repair, 43
 - cardiac rehabilitation, 45
 - CNS, 42, 43
 - cortical activity, 44
 - deficits, 43

- Sensorimotor control (*cont.*)
 - determinants of, 44
 - M1 lesions, 43, 44
 - neurophysiological changes, 42
 - persisting disability, 45
 - PMd activity, 44
 - standard discipline-specific therapy, 44, 45
 - walking program, 45
- somatosensory system, 37, 38
- thalamic lesions, 38
- upper limb dysfunction, 37
- ventroposterolateral nucleus, 38, 39
- Short-term memory, 181
- Sickle cell disease, 217–218
- Sickness impact profile (SIP), 245
- Signal-to-noise ratio (SNR), 258
- Silent brain infarcts, 6
- Single photon emission computed tomography (SPECT), 180
- SLT. *See* Speech-language therapy (SLT)
- Spatial errors, 55
- Spatial neglect syndrome
 - anatomy
 - critical lesions, 81–84
 - disconnection syndrome, 84–85
 - attention-based models, 74, 75
 - classic case of
 - cancellation task, 72, 73
 - causes, 71, 72
 - disorder of consciousness, 71
 - extinction disorder, 72
 - line bisection and figure copying, 72, 73
 - sub-syndromes, 72, 73
 - vision impairments, 72
 - deficits of
 - impaired time perception, 77, 79
 - nonspatial sustained attention, 75–76
 - representational updation, 79–82
 - spatial working memory, 76–78
 - symptoms constellation, 74
 - definition, 71
 - double-step saccade task, 80
 - elevator counting task, 76
 - mental models, 79–81, 88
 - recovery process
 - limb restriction, 85
 - neck muscle vibration and caloric stimulation, 85
 - prism adaptation, 85–88
 - rehabilitation, 85–88
 - remapping, 80
 - saccadic remapping, 80, 81
- Spatial working memory (SWM), 76–78
- Speech emotion disorders
 - expression, 123–125
 - prosody
 - alternate hypothesis, 121
 - case study, 120
 - phonemes, 120
 - propositional messages, 120
 - RHD and LHD patients, 121, 122
 - syntactic-propositional prosody, 121
 - verbal stimuli, 122–123
- Speech-language therapy (SLT), 107–108
- Stroke
 - clinical presentation, 11
 - complications, 11
 - definition, 5
 - epidemiology
 - age-adjusted mortality rates, 2–4
 - developed countries, 2
 - United States, 3
 - etiology, 5–8
 - historical perspective, 1–2
 - imaging investigations, 11–12
 - management, 12
 - pathophysiology, 10–11
 - risk factors, 8–10
- Stroke impact scale (SIS), 289
- Stroke trials
 - acetylsalicylic acid, 284
 - blood pressure control, 284
 - clinical outcomes and comorbid burden, 285
 - functional activity measures
 - Acute Stroke Ischemic NXY-059 Treatment, 304
 - British Aneurysm Nimodipine Trial, 302
 - carotid surgery trials, 303–304
 - decompressive craniectomy trials, 304–305
 - International Stroke Trial, 302
 - International Subarachnoid Aneurysm Trial, 303
 - International Surgical Trial In Intracerebral Hemorrhage, 304
 - health research methods, 286–287
 - measurement and outcome scales
 - AHA.SOC, 290
 - Chedoke-McMaster stroke assessment scale, 290
 - Frenchay activities index, 290
 - impairment (disability) scales, 289
 - methodology, 287–288
 - Modified Rankin Scale (mRS), 287
 - NIHSS, 288

physical impairment and functional activity, 289
 quality of life, 290–301
 stroke impact scale, 289
 WHO international classification, 289
 neuroplasticity, 284
 prognostic factors, 284–285
 tissue plasminogen activator, 302
 Subarachnoid hemorrhage (SAH), 142–143.
See also Hemorrhagic stroke
 Sustained-attention to response task (SART), 265
 SWM. *See* Spatial working memory (SWM)
 Systemic lupus erythematosus (SLE), 215

T

Tenecteplase, 19
 Thalamic infarcts, 141–142
 Thalamus
 hippocampal damage, 163
 intracerebral hemorrhage, 202
 left *vs.* right, 164
 medial dorsal thalamic nuclei, 161
 medial temporal lobe structures, 162
 Three-dimensional time of flight angiography (3DTOF), 263
 Thrombectomy, 20–24
 Thrombolysis. *See* Treatment
 Tissue plasminogen activator, 302
 Transcortical aphasia, 101
 Transcortical motor aphasia, 124
 Transcortical sensory aphasia, 124
 Transient ischemic attacks (TIAs), etiology, 6
 Treatment
 aim, 15
 hemorrhagic stroke

 acute medical management, 28
 core area, 15
 ICH, 24, 26, 27
 IVH, 28
 SAH, 24, 27
 surgical treatment, 29–30
 ischemic stroke
 acute medical management, 16–17
 arterial occlusion, 16
 core area, 15
 decompressive craniectomy, 24–26
 intra-arterial and mechanical thrombolysis, 20–24
 intravenous thrombolysis, 18–19
 Tricyclic antidepressant (TCA), 230

U

UK guidelines, 332, 333

V

Ventroposterolateral nucleus (VPL), 38, 39
 Verbal memory, 181, 182
 Visual memory, 181, 182
 Visual Reproduction subtest, 181
 Visuospatial facial perceptual disorder, 126, 127
 Voxel-based lesion symptom mapping (VLSM), 265
 Voxel-based morphometry (VBM), 265, 266

W

Wernicke's aphasia, 100, 121, 124
 Wisconsin Card Sorting Test (WCST), 144, 184, 205